Glycopathology of HCC: identification of the source cells of serum fucosylation

HCC 糖病理学:血清岩藻糖基化来源细胞的鉴定

基本信息

  • 批准号:
    9893835
  • 负责人:
  • 金额:
    $ 61.56万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-03-14 至 2024-02-29
  • 项目状态:
    已结题

项目摘要

Abstract: In the Annual Report to the Nation on the Status of Cancer, mortality from Hepatocellular carcinoma (HCC) increased at an annual rate of 2.8% in men and 2.2% in women, making it the cancer with the greatest increase in mortality in the United States (USA) over the last 10 years. The occurrence of liver cancer is predicted to continue rising in the USA and will exceed 50,000 cases by 2021. The majority of HCC arises in the background of liver fibrosis and cirrhosis, usually associated with chronic viral infection (hepatitis B and hepatitis C virus) or nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) associated with obesity. Our laboratory has shown alterations in both core and outer-arm fucosylation in HCC. These glycan modifications have promise as biomarkers of cancer and are actively being commercialized by a number of groups (including us). We have a developed a diagnostic panel that is comprised of clinical data along with one additional novel biomarker, fucosylated kininogen, that dramatically improves upon the detection of HCC, and in particular, the identification of those with early stage HCC. In an effort to identify the source of fucosylated serum glycoprotein, we have developed a novel method for tissue-based glycan analysis. In an analysis of 145 HCC tissue and 112 adjacent control or cirrhotic tissue control samples, we have identified two major changes in the N-linked glycan family that are associated with HCC. The first change observed was increased levels of fucosylation, a modification also often observed in serum of patients with HCC. However, ~50% of the tissue samples analyzed had no increase in fucose. Often these tumors without increased fucosylation had increases in tetra-antennary glycan. We hypothesize that the genetic heterogeneity of the tumor might have an impact upon the glycan heterogeneity in the tissue and serum. Consequently, the glycans may not only be used as biomarkers for the early detection of cancer but offer information into the specific genetics of the cancer. In this application, we will link the glycomic changes observed in both tissue and serum with the underlying genetic changes. As we will have matching tissue and serum, we will be able to determine if our current biomarker panel is capable of identifying fucose negative HCC. Lastly, we will utilize several proteomic and glycomic methods to identify biomarkers for cancer without increased levels of fucosylation.
文摘:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD R. DRAKE其他文献

RICHARD R. DRAKE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD R. DRAKE', 18)}}的其他基金

Targeted Isolation and Identification of Sialylated Glycoproteins in Cancer Tissues, Cells and Biofluids
癌症组织、细胞和生物液中唾液酸化糖蛋白的靶向分离和鉴定
  • 批准号:
    10358217
  • 财政年份:
    2022
  • 资助金额:
    $ 61.56万
  • 项目类别:
Targeted Isolation and Identification of Sialylated Glycoproteins in Cancer Tissues, Cells and Biofluids
癌症组织、细胞和生物液中唾液酸化糖蛋白的靶向分离和鉴定
  • 批准号:
    10592315
  • 财政年份:
    2022
  • 资助金额:
    $ 61.56万
  • 项目类别:
Proteomics Core
蛋白质组学核心
  • 批准号:
    10395946
  • 财政年份:
    2020
  • 资助金额:
    $ 61.56万
  • 项目类别:
Proteomics Core
蛋白质组学核心
  • 批准号:
    10608991
  • 财政年份:
    2020
  • 资助金额:
    $ 61.56万
  • 项目类别:
Glycopathology of HCC: identification of the source cells of serum fucosylation
HCC 糖病理学:血清岩藻糖基化来源细胞的鉴定
  • 批准号:
    10576851
  • 财政年份:
    2019
  • 资助金额:
    $ 61.56万
  • 项目类别:
Glycopathology of HCC: identification of the source cells of serum fucosylation
HCC 糖病理学:血清岩藻糖基化来源细胞的鉴定
  • 批准号:
    10361210
  • 财政年份:
    2019
  • 资助金额:
    $ 61.56万
  • 项目类别:
Detection and Histopathology Localization of O-Glycans and Glycosaminoglycans in Tissues
组织中 O-聚糖和糖胺聚糖的检测和组织病理学定位
  • 批准号:
    9320983
  • 财政年份:
    2016
  • 资助金额:
    $ 61.56万
  • 项目类别:
Detection and Histopathology Localization of O-Glycans and Glycosaminoglycans in Tissues
组织中 O-聚糖和糖胺聚糖的检测和组织病理学定位
  • 批准号:
    9166181
  • 财政年份:
    2016
  • 资助金额:
    $ 61.56万
  • 项目类别:
Defining an Integrated Allostatic Load Index with Immune and Tumor Microenvironment Factors
定义具有免疫和肿瘤微环境因素的综合稳态负荷指数
  • 批准号:
    9145866
  • 财政年份:
    2016
  • 资助金额:
    $ 61.56万
  • 项目类别:
Defining an Integrated Allostatic Load Index with Immune and Tumor Microenvironment Factors
定义具有免疫和肿瘤微环境因素的综合稳态负荷指数
  • 批准号:
    10562431
  • 财政年份:
    2016
  • 资助金额:
    $ 61.56万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 61.56万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 61.56万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 61.56万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 61.56万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 61.56万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 61.56万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 61.56万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 61.56万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 61.56万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 61.56万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了